ExpressCells completes Series A round with $1.2M total raise

▤ Summary

ExpressCells Inc., a private genetic engineering company that creates knock-in cell lines for drug discovery, has completed its Series A round, raising $400,000 in addition to the $800,000 first close announced on July 1. Additional investors include the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania. Since announcing the first close, the company has opened its lab and begun commercializing knock-in cell lines. As part of this investment, Tom Anderson of Robin Hood Ventures has joined the Board of Directors of ExpressCells. Tom was previously President & CEO of Ranir-DCP Corporation, and EVP / COO with Claneils Lander Company, Inc.

$ Funding

▦ Linked Companies